Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 381 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Escalation Therapies Group Clear all
Completed Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

NCT00611026
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine ER, Placebo, Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
102
States / cities
Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Sep 24, 2026, 7:10 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

NCT05773040
View directory record Official record
Conditions
Lymphomas, B-cell Lymphomas
Interventions
JV-213, Leukapheresis
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 24, 2026, 7:10 AM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00002602
View directory record Official record
Conditions
Prostate Cancer
Interventions
3D-CRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,084 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2013
U.S. locations
213
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 24, 2026, 7:10 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

NCT06194877
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Interventions
BGB-3245, Panitumumab
Drug
Lead sponsor
MapKure, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Duarte, California • Durham, North Carolina • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 24, 2026, 7:10 AM EDT
Terminated Phase 1 Interventional

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

NCT06110195
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck
Interventions
Xevinapant, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 24, 2026, 7:10 AM EDT
Suspended Phase 1Phase 2 Interventional

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

NCT04539236
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Lenalidomide, Luspatercept
Drug
Lead sponsor
Mikkael Sekeres, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 24, 2026, 7:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

NCT00401401
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Cancer
Interventions
zalutumumab, cisplatin, Radiotherapy
Drug · Procedure
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 22, 2011 · Synced Sep 24, 2026, 7:10 AM EDT
Withdrawn Not applicable Interventional

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01918657
View directory record Official record
Conditions
Peanut Allergy
Interventions
walnut powder
Drug
Lead sponsor
Jonathan Spergel
Other
Eligibility
6 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Sep 24, 2026, 7:10 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 24, 2026, 7:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

NCT03843775
View directory record Official record
Conditions
Advanced BRAF Mutant Cancers
Interventions
Binimetinib, Encorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 24, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer

NCT01162200
View directory record Official record
Conditions
Early Stage Breast Cancer
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 24, 2026, 7:10 AM EDT
Recruiting Phase 2 Interventional

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

NCT07169279
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 24, 2026, 7:10 AM EDT
Terminated Phase 1 Interventional

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06630247
View directory record Official record
Conditions
Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis
Interventions
XL495, ADC cytotoxic agents
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 24, 2026, 7:10 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCB160058, Standard disease-directed therapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 24, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

NCT01783587
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Afatinib, Docetaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 24, 2026, 7:10 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

NCT04471415
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
Interventions
DRP-104, atezolizumab
Drug · Biological
Lead sponsor
Dracen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Scottsdale, Arizona • Los Angeles, California • Kissimmee, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 24, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

NCT02338349
View directory record Official record
Conditions
Advanced ER+, HER2-Negative Breast Cancer
Interventions
Elacestrant
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 24, 2026, 7:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 24, 2026, 7:10 AM EDT
Terminated Not applicable Interventional

Sublingual Immunotherapy for Food Allergy

NCT00736281
View directory record Official record
Conditions
Food Allergies
Interventions
Food Drops: Food Allergens (peptides)
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
4 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 24, 2026, 7:10 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151
View directory record Official record
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 24, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

NCT03479892
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0194-0499, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 24, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

NCT03972306
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Ocrelizumab, rHuPH20
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
18
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 24, 2026, 7:10 AM EDT
Terminated Phase 1 Interventional

Study of INCA 0186 in Subjects With Advanced Solid Tumors

NCT04989387
View directory record Official record
Conditions
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
Interventions
INCA00186, Retifanlimab, INCB106385
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 24, 2026, 7:10 AM EDT
Recruiting Phase 3 Interventional

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
ICS-LABA, benralizumab, Placebo for Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 24, 2026, 7:10 AM EDT